Up to 4 Million People in the US Living with HCV, Which Can Progress to Cirrhosis, End-Stage Liver Disease and Liver Cancer if Left Untreated ...
C-FORWARD is the Second Phase 3 Trial in the Global HCV Development Program; the First Phase 3 Trial, C-BEYOND, is Currently Enrolling Patients in the US and Canada Regimen has Potential Best-in-Class ...
Glecaprevir/pibrentasvir achieves high sustained virologic response rates in adults with acute HCV infection regardless of prior cure.
Atea Pharmaceuticals announced the ongoing enrollment in its Phase 3 C-BEYOND trial evaluating the combination of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV). Positive ...
“Nevertheless, these findings highlight the importance of treatment adherence, regular follow-up, and targeted prevention in order to reach the WHO [World Health Organization] HCV elimination goals,” ...
Nontargeted screening in emergency departments (EDs) identified significantly more new hepatitis C virus (HCV) infections than targeted screening, according to a randomized trial. Treatment completion ...
ED visits by individuals experiencing homelessness are associated with increased HCV screening uptake and seropositivity rates.
If we truly want to eliminate hepatitis C among persons who use drugs, we must also commit to addressing the complex realities of their lived experience. Offering HCV testing at clinical, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results